表纸
市场调查报告书

再生医疗的全球市场:2020年~2024年

Regenerative Medicine Market by Technology and Geography - Forecast and Analysis 2020-2024

出版商 TechNavio (Infiniti Research Ltd.) 商品编码 321466
出版日期 内容资讯 英文 120 Pages
订单完成后即时交付
价格
Back to Top
再生医疗的全球市场:2020年~2024年 Regenerative Medicine Market by Technology and Geography - Forecast and Analysis 2020-2024
出版日期: 2020年02月04日内容资讯: 英文 120 Pages
简介

全球再生医疗市场在2020年~2024年的预测期间内,预计将以20%的年复合成长率增长,达到95亿5,000万美元的规模。市场成长主要因素是慢性疾病的盛行率增加。此外,临床试验的增长有望推动市场增长。

本报告提供全球再生医疗市场相关调查分析,提供市场规模及成长率,市场趋势,推动市场要素,课题,市场机会验证,再加上主要供应商等相关的系统性资讯。

目录

摘要整理

  • 市场概况

市场情形

  • 市场生态系统
  • 价值链分析

市场规模

  • 市场定义
  • 市场区隔分析
  • 市场规模:2019年
  • 市场预测:2019-2024年的预测

波特的五力分析

  • 波特的五力分析摘要
  • 买主谈判力
  • 供应商谈判力
  • 新加入厂商的威胁
  • 替代品的威胁
  • 对手的威胁
  • 市场情况

市场区隔:各技术

  • 市场区隔
  • 比较:各技术市场规模与预测2019-2024
  • 以细胞及组织为主
  • 基因治疗
  • 市场机会:各技术

客户形势

  • 概要

各地区形势

  • 各地区市场区隔
  • 各地区比较:市场规模与预测2019-2024
  • 北美
  • 欧洲
  • 亚洲
  • 其他地区
  • 主要国家
  • 市场机会:各地区

成长要素,课题,及趋势

  • 市场成长要素
  • 数量的成长要素-需求主导型成长
  • 数量的成长要素-供给主导型成长
  • 数量的成长要素-外部要素
  • 数量的成长要素-需求转移到邻近市场
  • 价格上升要素-通货膨胀
  • 价格上升要素-从低价格单位转变到高价格单位
  • 市场课题
  • 市场趋势

业者情势

  • 概要
  • 业者情势
  • 形势的创新

供应商分析

  • 交易厂商
  • 供应商的市场定位
  • Allergan Plc
  • Amgen Inc.
  • 日立化成
  • Integra LifeSciences Holdings Corp.
  • Medtronic Plc
  • MiMedx Group Inc.
  • Organogenesis Holdings Inc.
  • Smith & Nephew Plc
  • 武田药品工业
  • Zimmer Biomet Holdings Inc.

附录

  • 调查范围
  • 美金的货币换算比率
  • 调查方法
  • 简称的清单

本网页内容可能与最新版本有所差异。详细情况请与我们联系。

目录
Product Code: IRTNTR41171

Technavio has been monitoring the global regenerative medicine market and it is poised to grow by USD 9.55 bn during 2020-2024, progressing at a CAGR of 20% during the forecast period. Our reports on global regenerative medicine market provides a holistic analysis, market size and forecast, trends, growth drivers, and challenges, as well as vendor analysis covering around 25 vendors.

The report offers an up-to-date analysis regarding the current global market scenario, latest trends and drivers, and the overall market environment. The market is driven by increasing prevalence of chronic diseases.

In addition, increasing number of clinical trials is anticipated to boost the growth of the global regenerative medicine market as well.

Market Segmentation

Technavio's global regenerative medicine market is segmented as below:

Technology

  • Cell and tissue-based
  • Gene therapy

Geographic segmentation

  • North America
  • Europe
  • Asia
  • ROW

Key Trends for global regenerative medicine market growth

This study identifies increasing number of clinical trials as the prime reasons driving the global regenerative medicine market growth during the next few years.

Prominent vendors in global regenerative medicine market

We provide a detailed analysis of around 25 vendors operating in the global regenerative medicine market, including some of the vendors such as Allergan Plc, Amgen Inc., Hitachi Chemical Co. Ltd., Integra LifeSciences Holdings Corp., Medtronic Plc, MiMedx Group Inc., Organogenesis Holdings Inc., Smith & Nephew Plc, Takeda Pharmaceutical Co. Ltd. and Zimmer Biomet Holdings Inc. .

The study was conducted using an objective combination of primary and secondary information including inputs from key participants in the industry. The report contains a comprehensive market and vendor landscape in addition to an analysis of the key vendors.

Technavio presents a detailed picture of the market by the way of study, synthesis, and summation of data from multiple sources by an analysis of key parameters such as profit, pricing, competition, and promotions. It presents various market facets by identifying the key industry influencers. The data presented is comprehensive, reliable, and a result of extensive research - both primary and secondary. Technavi's market research reports provide a complete competitive landscape and an in-depth vendor selection methodology and analysis using qualitative and quantitative research to forecast an accurate market growth.

Table of Contents

Executive Summary

  • Market Overview

Market Landscape

  • Market ecosystem
  • Value chain analysis

Market Sizing

  • Market definition
  • Market segment analysis
  • Market size 2019
  • Market outlook: Forecast for 2019 - 2024

Five Forces Analysis

  • Five Forces Summary
  • Bargaining power of buyers
  • Bargaining power of suppliers
  • Threat of new entrants
  • Threat of substitutes
  • Threat of rivalry
  • Market condition

Market Segmentation by Technology

  • Market segments
  • Comparison by Technology placement
  • Cell and tissue-based - Market size and forecast 2019-2024
  • Gene therapy - Market size and forecast 2019-2024
  • Market opportunity by Technology

Customer landscape

  • Overview

Geographic Landscape

  • Geographic segmentation
  • Geographic comparison
  • North America - Market size and forecast 2019-2024
  • Europe - Market size and forecast 2019-2024
  • Asia - Market size and forecast 2019-2024
  • ROW - Market size and forecast 2019-2024
  • Key leading countries
  • Market opportunity by geography

Drivers, Challenges, and Trends

  • Market drivers
  • Volume driver - Demand led growth
  • Volume driver - Supply led growth
  • Volume driver - External factors
  • Volume driver - Demand shift in adjacent markets
  • Price driver - Inflation
  • Price driver - Shift from lower to higher priced units
  • Market challenges
  • Market trends

Vendor Landscape

  • Overview
  • Vendor landscape
  • Landscape disruption

Vendor Analysis

  • Vendors covered
  • Market positioning of vendors
  • Allergan Plc
  • Amgen Inc.
  • Hitachi Chemical Co. Ltd.
  • Integra LifeSciences Holdings Corp.
  • Medtronic Plc
  • MiMedx Group Inc.
  • Organogenesis Holdings Inc.
  • Smith & Nephew Plc
  • Takeda Pharmaceutical Co. Ltd.
  • Zimmer Biomet Holdings Inc.

Appendix

  • Scope of the report
  • Currency conversion rates for US$
  • Research methodology
  • List of abbreviations

List of Exhibits:

  • 1.Key Finding 1
  • 2.Key Finding 2
  • 3.Key Finding 3
  • 4.Key Finding 4
  • 5.Key Finding 5
  • 6.Key Finding 6
  • 7.Key Finding 7
  • 8.Market in focus
  • 9.Parent market
  • 10.Market characteristics
  • 11.Product / Service portfolio of key vendors included in the market definition
  • 12.Market segments
  • 13.Global - Market size and forecast 2019 - 2024 ($ million)
  • 14.Global market: Year-over-year growth 2019 - 2024 (%)
  • 15.Five forces analysis 2019 & 2024
  • 16.Bargaining power of buyers
  • 17.Bargaining power of suppliers
  • 18.Threat of new entrants
  • 19.Threat of substitutes
  • 20.Threat of rivalry
  • 21.Market condition - Five forces 2019
  • 22.Technology placement - Market share 2019-2024 (%)
  • 23.Comparison by Technology placement
  • 24.Cell and tissue-based - Market size and forecast 2019-2024 ($ million)
  • 25.Cell and tissue-based - Year-over-year growth 2019-2024 (%)
  • 26.Gene therapy - Market size and forecast 2019-2024 ($ million)
  • 27.Gene therapy - Year-over-year growth 2019-2024 (%)
  • 28. Market opportunity by Technology
  • 29.Customer landscape
  • 30.Market share by geography 2019-2024 (%)
  • 31.Geographic comparison
  • 32.North America - Market size and forecast 2019-2024 ($ million)
  • 33.North America - Year-over-year growth 2019-2024 (%)
  • 34.Europe - Market size and forecast 2019-2024 ($ million)
  • 35.Europe - Year-over-year growth 2019-2024 (%)
  • 36.Asia - Market size and forecast 2019-2024 ($ million)
  • 37.Asia - Year-over-year growth 2019-2024 (%)
  • 38.ROW - Market size and forecast 2019-2024 ($ million)
  • 39.ROW - Year-over-year growth 2019-2024 (%)
  • 40.Key leading countries
  • 41.Market opportunity by geography ($ million)
  • 42.Impact of drivers
  • 43.Impact of challenges
  • 44.Landscape disruption
  • 45.Industry risks
  • 46.Vendors covered
  • 47.Market positioning of vendors
  • 48.Allergan Plc - Overview (1/3)
  • 49.Allergan Plc - Overview (2/3)
  • 50.Allergan Plc - Overview (3/3)
  • 51.Allergan Plc - Business segments
  • 52.Allergan Plc - Key offerings
  • 53.Allergan Plc - Key customers
  • 54.Allergan Plc - Segment focus
  • 55.Amgen Inc. - Overview (1/3)
  • 56.Amgen Inc. - Overview (2/3)
  • 57.Amgen Inc. - Overview (3/3)
  • 58.Amgen Inc. - Business segments
  • 59.Amgen Inc. - Key offerings
  • 60.Amgen Inc. - Key customers
  • 61.Amgen Inc. - Segment focus
  • 62.Hitachi Chemical Co. Ltd. - Overview (1/3)
  • 63.Hitachi Chemical Co. Ltd. - Overview (2/3)
  • 64.Hitachi Chemical Co. Ltd. - Overview (3/3)
  • 65.Hitachi Chemical Co. Ltd. - Business segments
  • 66.Hitachi Chemical Co. Ltd. - Key offerings
  • 67.Hitachi Chemical Co. Ltd. - Key customers
  • 68.Hitachi Chemical Co. Ltd. - Segment focus
  • 69.Integra LifeSciences Holdings Corp. - Overview (1/3)
  • 70.Integra LifeSciences Holdings Corp. - Overview (2/3)
  • 71.Integra LifeSciences Holdings Corp. - Overview (3/3)
  • 72.Integra LifeSciences Holdings Corp. - Business segments
  • 73.Integra LifeSciences Holdings Corp. - Key offerings
  • 74.Integra LifeSciences Holdings Corp. - Key customers
  • 75.Integra LifeSciences Holdings Corp. - Segment focus
  • 76.Medtronic Plc - Overview (1/3)
  • 77.Medtronic Plc - Overview (2/3)
  • 78.Medtronic Plc - Overview (3/3)
  • 79.Medtronic Plc - Business segments
  • 80.Medtronic Plc - Key offerings
  • 81.Medtronic Plc - Key customers
  • 82.Medtronic Plc - Segment focus
  • 83.MiMedx Group Inc. - Overview (1/3)
  • 84.MiMedx Group Inc. - Overview (2/3)
  • 85.MiMedx Group Inc. - Overview (3/3)
  • 86.MiMedx Group Inc. - Product and service
  • 87.MiMedx Group Inc. - Key offerings
  • 88.MiMedx Group Inc. - Key customers
  • 89.MiMedx Group Inc. - Segment focus
  • 90.Organogenesis Holdings Inc. - Overview (1/3)
  • 91.Organogenesis Holdings Inc. - Overview (2/3)
  • 92.Organogenesis Holdings Inc. - Overview (3/3)
  • 93.Organogenesis Holdings Inc. - Business segments
  • 94.Organogenesis Holdings Inc. - Key offerings
  • 95.Organogenesis Holdings Inc. - Key customers
  • 96.Organogenesis Holdings Inc. - Segment focus
  • 97.Smith & Nephew Plc - Overview (1/3)
  • 98.Smith & Nephew Plc - Overview (2/3)
  • 99.Smith & Nephew Plc - Overview (3/3)
  • 100.Smith & Nephew Plc - Business segments
  • 101.Smith & Nephew Plc - Key offerings
  • 102.Smith & Nephew Plc - Key customers
  • 103.Smith & Nephew Plc - Segment focus
  • 104.Takeda Pharmaceutical Co. Ltd. - Overview (1/3)
  • 105.Takeda Pharmaceutical Co. Ltd. - Overview (2/3)
  • 106.Takeda Pharmaceutical Co. Ltd. - Overview (3/3)
  • 107.Takeda Pharmaceutical Co. Ltd. - Business segments
  • 108.Takeda Pharmaceutical Co. Ltd. - Key offerings
  • 109.Takeda Pharmaceutical Co. Ltd. - Key customers
  • 110.Takeda Pharmaceutical Co. Ltd. - Segment focus
  • 111.Zimmer Biomet Holdings Inc. - Overview (1/3)
  • 112.Zimmer Biomet Holdings Inc. - Overview (2/3)
  • 113.Zimmer Biomet Holdings Inc. - Overview (3/3)
  • 114.Zimmer Biomet Holdings Inc. - Product and service
  • 115.Zimmer Biomet Holdings Inc. - Key offerings
  • 116.Zimmer Biomet Holdings Inc. - Key customers
  • 117.Zimmer Biomet Holdings Inc. - Segment focus
  • 118.Currency conversion rates for US$
  • 119.Research Methodology
  • 120.Validation techniques employed for market sizing
  • 121.Information sources
  • 122.List of abbreviations
Back to Top